Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages

被引：4
|
作者：
Ly, Andrew [1 ]
Sanber, Khaled [2 ]
Tsai, Hua-Ling [2 ]
Ondo, Angela [2 ]
Mooney, Kathy [2 ]
Shedeck, Audra [2 ]
Baker, Julie [2 ]
Imus, Philip Hollingsworth [2 ]
Wagner-Johnston, Nina [2 ]
Jain, Tania [2 ,3 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies & Bone Marrow Transplanta, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies & Bone Marrow Transplanta, 1650 Orleans St,Room 3M88, Baltimore, MD 21287 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 203卷 / 04期
关键词：
D O I：
10.1111/bjh.19090
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：688 / 692
页数：5
相关论文
共 50 条
  • [21] TO THE EDITOR: CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy COMMENT
    Thapa, Bicky
    Caimi, Paolo F.
    Ardeshna, Kirit M.
    Solh, Melhem
    Carlo-Stella, Carmelo
    Kahl, Brad S.
    Hamadani, Mehdi
    BLOOD ADVANCES, 2020, 4 (16) : 3850 - 3852
  • [22] Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy
    Leahy, Allison Barz
    Devine, Kaitlin J.
    Li, Yimei
    Liu, Hongyan
    Myers, Regina
    DiNofia, Amanda
    Wray, Lisa
    Rheingold, Susan R.
    Callahan, Colleen
    Baniewicz, Diane
    Patino, Maria
    Newman, Haley
    Hunger, Stephen P.
    Grupp, Stephan A.
    Barrett, David M.
    Maude, Shannon L.
    BLOOD, 2022, 139 (14) : 2173 - 2185
  • [23] TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma
    Shouval, Roni
    Tomas, Ana Alarcon
    Fein, Joshua A.
    Flynn, Jessica
    Markovits, Ettai
    Mayer, Shimrit
    Afuye, Aishat Olaide
    Alperovich, Anna
    Anagnostou, Theodora
    Batlevi, Connie Lee
    Dahi, Parastoo B.
    Devlin, Sean M.
    Fingrut, Warren
    Giralt, Sergio A.
    Lin, Richard J.
    Salles, Gilles
    Sauter, Craig S.
    Scordo, Michael
    Shah, Gunjan L.
    Shah, Nishi
    Shouval, Ruth Scherz
    van den Brink, Marcel
    Perales, Miguel-Angel
    Palomba, Maria Lia
    BLOOD, 2021, 138
  • [24] CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
    Liang, Yun
    Liu, Hui
    Lu, Zheming
    Lei, Wen
    Zhang, Chaoting
    Li, Ping
    Liang, Aibin
    Young, Ken H.
    Qian, Wenbin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [25] CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
    Yun Liang
    Hui Liu
    Zheming Lu
    Wen Lei
    Chaoting Zhang
    Ping Li
    Aibin Liang
    Ken H. Young
    Wenbin Qian
    Journal of Hematology & Oncology, 14
  • [26] TOXICITIES AND OUTCOME AFTER CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR NEUROLYMPHOMATOSIS
    Kaulen, Leon D.
    Karschnia, Philipp
    Doubrovinskaia, Sofia
    Wick, Wolfgang
    Martinez-Lage, Maria
    Shankar, Ganesh
    Abramson, Jeremy S.
    Frigault, Matthew J.
    Dietrich, Jorg
    NEURO-ONCOLOGY, 2024, 26
  • [27] Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
    Domizi, Pablo
    Jager, Astraea
    Sarno, Jolanda
    Mullighan, Charles G.
    Grupp, Stephan
    Sotillo, Elena
    Barrett, David M.
    Davis, Kara L.
    BLOOD, 2019, 134
  • [28] Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).
    Bock, Allison Marie
    Raj, Sandeep
    Giri, Sharmila
    Leslie, Lori Ann
    Patel, Dilan Anil
    Iqbal, Madiha
    Grover, Natalie Sophia
    Hu, Boyu
    Perales, Miguel-Angel
    Nowakowski, Grzegorz S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma
    Gazeau, Nicolas
    Mitra, Suman
    Nudel, Morgane
    Tilmont, Remi
    Chauvet, Paul
    Srour, Micha
    Moreau, Anne-Sophie
    Varlet, Pauline
    Alidjinou, Enagnon Kazali
    Manier, Salomon
    Morschhauser, Franck
    Labalette, Myriam
    Yakoub-Agha, Ibrahim
    Beauvais, David
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (02) : 434 - 436
  • [30] The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma
    Lutfi, Forat
    Holtzman, Noa G.
    Kansagra, Ankit J.
    Ali, Moaath Mustafa
    Bukhari, Ali
    Yan, Jingsheng
    Samanta, Santanu
    Gottlieb, David
    Kim, Dong W.
    Matsumoto, Lisa R.
    Gahres, Natalie
    Ruehle, Kathleen
    Lee, Seung T.
    Kocoglu, Mehmet H.
    Atanackovic, Djordje
    Yared, Jean A.
    Hardy, Nancy M.
    Molitoris, Jason
    Mohindra, Pranshu
    Rapoport, Aaron P.
    Dahiya, Saurabh
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 405 - 412
12345